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Allergic rhinitis (AR) is the most common chronic pediatric disorder. The International Study for Asthma and Allergies in Childhood 
phase III found that the global average of current rhinoconjunctivitis symptoms in the 13-14 year age-group was 14.6% and the average 
prevalence of rhinoconjunctivitis symptoms in the 6-7 year age-group was 8.5%. In addition to classical symptoms, AR is associated 
with a multidimensional impact on the health related quality of life in children. AR affects the quality of sleep in children and frequently 
leads to day-time fatigue as well as sleepiness. It is also thought to be a risk factor for sleep disordered breathing. AR results in increased 
school absenteeism and distraction during class hours. These children are often embarrassed in school and have decreased social 
interaction which significantly hampers the process of learning and school performance. All these aspects upset the family too. Multiple 
co-morbidities like sinusitis, asthma, conjunctivitis, eczema, eustachian tube dysfunction and otitis media are generally associated 
with AR. These mostly remain undiagnosed and untreated adding to the morbidity. To compound the problems, medications have 
bothersome side effects which cause the children to resist therapy. Children customarily do not complain while parents and health 
care professionals, more often than not, fail to accord the attention that this not so trivial disease deserves. AR, especially in developing 
countries, continues to remain a neglected disorder. 
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IntroductIon
The Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 
updated document estimates that there are 500 million subjects 
in this world who suffer with allergic rhinitis (AR) [1]. Data 
suggests that AR is the most common chronic disorder in the 
pediatric population with up to 40% of children affected [1]. The 
disease along with associated co-morbidities has a profound 
impact on the daily lives of children. Irritability, sadness, 
impairment of sleep and limitation of activities at school as well 
as home are often seen in these children. AR results in day-time 
fatigue and impairment of cognition and memory in children 
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which significantly affect the learning process and thus impacts 
on school performance and all these aspects upset the family 
[2].  Many of these problems go completely unnoticed as children 
often fail to share them at home or at school. Furthermore, 
adverse effects of medications used for treatment of AR often 
compound these problems [2]. Although AR greatly impacts life 
at home, school and even while sleeping, it is treated as a trivial 
and a commonplace disorder. Consequently, it does not receive 
the attention it deserves from the patient, the family as well as the 
health care professionals, especially in developing countries like 
India [3].
Burden of allergic rhinitis in children of the Asia-Pacific 
region 
The International Study for Asthma and Allergies in Childhood 
(ISAAC) phase III [4] found that the global average of current 
rhinoconjunctivitis symptoms in the 13-14 year age-group was 
14.6% and the average prevalence of rhinoconjunctivitis symptoms 
in the 6-7 year age-group was 8.5%. The prevalence of AR in 
certain centres approached more than 50%. Higher prevalence of 
severe rhinoconjunctivitis was seen in lower and middle income 
countries particularly in Africa and Latin America [4]. In India, the 
ISAAC phase I [5] revealed that 12.5% children in the 6-7 year age-
group and 18.6% in the 13-14 year age-group had nasal symptoms 
alone, while allergic rhinoconjunctivitis was seen in 3.2% and 6.3% 
children in these age-groups respectively. In ISAAC phase III [4], 
the prevalence of current nose symptoms increased to 12.9% and 
23.6% in the 6-7 and 13-14 year age-groups respectively, while the 
prevalence of allergic rhinoconjunctivitis increased to 3.9% and 
10.4% respectively. Among the Asia- Pacific countries, the ISAAC 
phase III data [4] revealed that allergic rhinoconjunctivitis was 
lowest in Indonesia with prevalence ranging from 3.6% in the 6-7 
year age-group to 4.8% in the 13-14 year age-group. In contrast, 
the highest prevalence was documented in Taiwan which ranged 
from 24.2% in the 6-7 year age-group to 17.8% in the 13-14 year 
age-group [4]. Most countries in this region showed an increase in 
the prevalence of allergic rhinoconjunctivitis between the ISAAC 
phase I and III studies (Table 1) [6]. In an 11 Asian countries study 
in selected centers, the prevalence of AR ranged from 10 to 46% 
in children and was more common in boys [7]. Several studies of 
AR in children from Asia confirm the enormity of burden of this 
disease. In Taiwan, the mean one-year and overall 8-year (2000 
to 2007) prevalence of AR in children and adolescents was 11.3% 
and 37.8% respectively [8]. Similarly in China, a study in 24,290 
children showed that the prevalence ranged from 7.83% to 20.42% 
[9]. However, the ISAAC phase III study in Tibet [10] revealed 
that allergic rhinoconjunctivitis was present in 5.2% of the 3196 
children in the 13-14 year age-group. The authors state that this 
was the lowest prevalence in the ISAAC phase III study worldwide 
[10].
Table 1. Prevalence (%) of the symptoms of allergic rhinoconjunctivitis in children of Indian subcontinent, Asia-Pacific and the Oceanic 
countries during the ISAAC phases I and III
ISAAC phase I ISAAC phase III
Age-group    6-7 years   13-14 years    6-7 years   13-14 years
India   3.2   6.3   3.9 10.0
Hong Kong 13.7 24.0  17.7 22.6
Indonesia   3.8   5.3   3.6   4.8
Japan   7.8 14.9  10.6  17.6
Malaysia   4.1  13.9    4.8 16.2
Philippines  - 15.3 - 11.1
Singapore   8.5 15.1   8.7 16.5
South Korea   9.8 10.2   8.7  11.6 
Taiwan 14.6  11.7  24.2 17.8
Thailand   7.3 15.5 10.4 21.0
China -   8.1 - 10.4
Austrailia   9.8 - 12.9 -
New Zealand   9.5 19.1 11.4 18.0
Adapted from reference [6]. ISAAC, International Study for Asthma and Allergies in Childhood.apallergy.org
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clinical profile of the patients and classification
The ARIA update 2008 [1] classifies AR on the basis of frequency 
and severity. Mygind [11] first proposed classifying AR on the basis 
of predominant clinical symptoms. He proposed calling those with 
predominant blockage as ‘blockers’ and those with runny nose 
as ‘sneezers and runners’ [11]. We sketched the profile of these 
two clinical presentations in 114 adults with AR [12] and found 
that almost two-third 72/114 (63%) were ‘sneezers and runners’ 
while 42/114 (37%) were ‘blockers’. ‘Sneezers and runners’ had 
significantly more sneezing, rhinorrhoea, itchy nose, eyes and 
palate. This group had a significantly more family history of atopy, 
seasonal disease and sensitivity to seasonal allergens like pollen. 
In contrast, ‘blockers’ had significantly more nasal blockade, 
thick nasal mucus, and post nasal drip. In addition, ‘blockers’ had 
significantly more sensitisation to perennial allergens like fungi 
and house dust mite and had perennial disease [12]. Recently, we 
evaluated 126 school going children with AR and/or asthma, of 
whom 14 (11.1%) had AR only, 100 (79.3%) had concomitant AR 
and asthma, while 12 (9.5%) had only asthma. On categorisation, 
46 (40.4%) were classified as ‘sneezers and runners’ while 68 (59.6%) 
were classified as ‘blockers’. ‘Sneezers and runners’ had more 
sneezing (100% vs. 85.3%) and itchy nose (63% vs. 54.4%), while 
‘blockers’ had more persistent disease (52.9% vs. 32.6%), post 
nasal drip (67.6% vs. 54.3%), loss of smell (22.1% vs. 10.9%), loss of 
taste (20.6% vs. 10.9%) and nasal quality of voice (14.7% vs. 4.3%). 
However, the differences did not achieve significance. On CT-PNS, 
sinusitis (Fig. 1) was recorded in 78/126 (61.9%) children [13].
Sleep disturbances
Both adults and children with AR have disturbances in sleep. 
Although the exact mechanisms of sleep impairment due to AR is 
not known, uncontrolled symptoms especially nasal congestion 
are thought to be responsible. The medications used may also 
compound the problems [14-17]. In a study in 39 children with 
habitual snoring, 14 (36%) had a positive radioallergosorbent test 
for allergens [14]. Children with atopy had higher prevalence of 
obstructive sleep apnea syndrome (OSAS) (57% vs. 40%; x
2 = 9.11, 
p < 0.01). The authors postulated that allergy was a risk factor for 
the presence of OSAS in the children [14]. A questionnaire based 
survey in Greece [15] involving parents of 3,680 children revealed 
that habitual snoring was present in 5.3%, 4%, and 3.8% in the 
children of 1-6, 7-12, and 13-18 year age-groups respectively. 
This study also found that chronic rhinitis was one of the most 
important risk factors for habitual snoring (odds ratio [OR] = 
2.1, confidence interval [CI] = 1.6-2.7). Intranasal corticosteroids 
(INCS) usage in children with AR appears to have an objective 
improvement in sleep parameters on polysomnography with a 
decrease of mean number of sleep arousals per h from a baseline 
of 8.4 to 1.2 (p = 0.005) [16]. In our study [13], parents reported 
sleep disturbances in 70/114 (61.4%) school going children with 
AR. Problems with sleep would heighten daytime somnolence and 
impair cognition which in turn may result in behavioral problems [2, 
17, 18].
Learning disabilities and problems at school
The symptoms of AR like nasal blockade, itching, rhinorrhoea 
and sneezing cause severe distraction during class hours. 
Uncontrolled symptoms at night leading to sleep loss and 
secondary daytime fatigue may also contribute to learning 
impairment similarly. Apart from absenteeism from the class, 
even when present during class hours, the child has decreased 
productivity. Complications of AR like sinusitis, eustachian 
dysfunction and associated conductive hearing loss may enhance 
the learning dysfunction [2]. Irritability, distraction, fatigue increase 
absenteeism and along with embarrassment at the school result 
in impaired school performance in these children. This can be 
compounded by the side effects of medication used for AR. The 
recreational activities of children with AR are often limited which 
leads to diminished social interaction and consequent isolation 
[2, 17]. Even in adults with AR there is slow speed of cognitive 
processing and impairment in working memory during the 
Fig. 1. Coronal CT of the paranasal sinuses in a 7-year-old child showing 
extensive mucosal thickening within all paranasal sinuses, ostiomeatal 
complexes and nasal cavity. apallergy.org
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ragweed pollen season [18]. 
The presence of sleep abnormalities in AR along with nocturnal 
snoring and hypoxia also affect the school performance of a child 
[2, 19]. Allergy and daytime nasal obstruction are independent 
risk factors for sleep disordered breathing ranging from habitual 
snoring to obstructive sleep apnoea [14, 15]. A study [19] on 1,144 
school children assessed the association of habitual snoring, 
intermittent hypoxia and academic performance. Of 1,129 children 
in whom information on snoring was available, 410 (36.3%) 
never snored, 605 (53.6%) snored occasionally, 89 (7.9%) snored 
frequently and 25 (2.2%) children always snored. The “always 
snorers” had poorer academic performance in mathematics 
(OR: 3.6, 95% CI: 1.3-10.1), science (OR: 4.3, 95% CI: 1.3-14.6), and 
spelling (OR: 3.5, 95% CI:1.2-10.3). “Frequent snorers” had poorer 
academic performance in mathematics (OR: 2.4, 95% CI: 1.3-
4.7) and spelling (OR: 2.0, 95% CI: 1.04-3.8). This study showed a 
significant association between snoring, with or without hypoxia, 
and poor academic performance [19]. It is therefore not surprising, 
that a study done on 9,538 adolescent students in 2007 revealed 
that patients with nasal symptoms severe enough to cause activity 
limitation had poorer grades especially those on anti-allergy 
medications as compared to normal subjects [20]. 
We used the Work Productivity and Activity Impairment 
Questionnaire - Allergy Specific to study the activity impairment at 
school and home in 114 school-going children with AR. The mean 
percent of class hours missed by children in the preceding week as 
a result of the symptoms of AR was 11.6 h (SD ± 20.0). Even when 
present in class, children with AR suffered a mean impairment of 
36.8% (SD ± 20.6).  In total, the mean classroom impairment was 
41.52% (SD ± 23.7). At home the children suffered a 35% (SD ± 
20.7) work impairment. This highlights the enormity of activity 
limitation in children as reflected by the class time missed and 
impairment during class hours as a result of AR [13]. This not so 
trivial disease is responsible for a huge loss of work productivity 
and absenteeism from school. In 1994, in USA alone, AR accounted 
for approximately 824,000 missed school days in children [21].
Impact on quality of life 
There is an immense difference between the level of actual 
disability that the child faces and that what is perceived by 
the care-givers and treating physicians. Allergic rhinitis too 
encompasses a spectrum of problems that go beyond the classical 
symptoms of the disease, and are best assessed by measuring 
the health related quality of life (QOL). Various disease specific 
questionnaires [22, 23] have been developed for the different 
aspects of QOL issues in children and adolescents with AR viz. 
physical, emotional, sleep problems and activity limitation. 
Assessment of these parameters help in knowing patients’ own 
perception of the disease, and help provide vital information which 
cannot be obtained from conventional clinical and functional 
tools. Though the impact of AR on QOL is multidimensional, 
the impairment is more in the physical domains than in the 
psychosocial domains of health [24-26]. Young children were 
less disturbed psychologically and emotionally, but were more 
troubled by taking medications and carrying tissues to blow their 
noses [24-26]. During a cross sectional analysis [26], the responses 
of parents or caregivers as well as the responses of 23 children 
and adolescents with AR were compared to those of normal age-
matched subjects using the generic Child Health Questionnaire 
(CHQ-PF50). The patients’ scores were found to be lower than that 
of the normal subjects in both the physical and the psychosocial 
summaries of the CHQ-PF50. This difference was more in the 
physical than in the psychosocial summary score. The investigators 
concluded that AR had a global negative impact on the QOL with 
a profound effect on physical aspect of the health in such patients. 
In addition, a negative effect on family relations was also observed 
[26].
The impairment in QOL in patients with AR increases during 
the pollen season in both seasonal as well as perennial AR. In 
seasonal AR, QOL is worse during the pollen season, as compared 
to perennial rhinitis [27]. Another study [28] involving 84 
children, in the age-group of 6 to 17 years, with seasonal allergic 
rhinoconjunctivitis, asthma and/or cutaneous manifestations were 
assessed before and during the grass pollen season using the 
pediatric allergic disease quality of life questionnaire. The health 
related QOL significantly correlated with the average pollen count 
in the previous week (regression coefficient 0.038, 95% CI 0.027-
0.049, p < 0.001) [28]. 
The productivity and ability to perform day-to-day activities 
in both children and adults is severely affected with a profound 
impact on the emotional aspects of the life [2, 17, 24-28]. Children 
with AR are unable to integrate socially and experience a feeling of 
isolation even within their families. This may be due to decreased 
participation in family events caused by AR, often resulting in 
family dysfunction [2, 17]. 
co-morbidities
Usually a part of a wide spectrum of systemic allergic diseases, apallergy.org
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AR rarely occurs in isolation and is associated with multiple 
co-morbidities. A close relation between AR and asthma is 
well documented [29]. Symptoms of rhinitis were observed 
in 28 to 78% of asthmatics, while 17-38% patients with AR 
had concomitant asthma [30]. A questionnaire based study 
conducted by us [31] showed that 75% of 405 children with 
asthma had coexistent rhinitis. Simultaneous occurrence of 
both the diseases was recorded in about three fourths of these 
children [31]. A retrospective analysis [32] has shown that children 
with AR younger than 7 years were at a 2 to 7 times greater risk 
of developing asthma. The occurrence of AR in children also 
increased the risk of persistence of childhood asthma by middle 
age [32].
In the ISAAC phase III study in the Indian subcontinent [4], 
among the 50,106 children in the age-group of 6-7 years, 1,183 
(2.4%) had symptoms of rhinoconjunctivitis alone, 554 (1.1%) had 
symptoms of both rhinoconjunctivitis and asthma, 174 (0.3%) 
had symptoms of rhinoconjunctivitis and eczema, and 174 (0.3%) 
had symptoms of all the three conditions. Among the 55,815 
children in the age-group of 13-14 years, 4,177 (7.5%) children had 
symptoms of rhinoconjunctivitis alone, 900 (1.6%) had symptoms 
of both rhinocinjunctivitis and asthma, 496 (0.9%) had symptoms 
of rhinoconjunctivitis and eczema, and 395 (0.70%) had symptoms 
of all three conditions. In other countries of the Asia Pacific region, 
of the 60,052 children in the age-group of 6-7 years, 3,520 (6.2%) 
children had symptoms of rhinoconjunctivitis alone, 1,117 (2.0%) 
had symptoms of both rhinocinjunctivitis and asthma, 884 (1.5%) 
had symptoms of rhinoconjunctivitis and eczema, and 494 (0.9%) 
had symptoms of all three conditions. Similarly in the age-group of 
13-14 years, among the 99,688 children, 8,581 (9.3%) children had 
symptoms of rhinoconjunctivitis alone, 2,135 (2.3%) had symptoms 
of both rhinocinjunctivitis and asthma, 1,064 (1.1%) had symptoms 
of rhinoconjunctivitis and eczema, and 530 (0.60%) had symptoms 
of all three conditions [4].
As highlighted in the ISAAC study, AR is commonly associated 
with conjunctivitis [4, 6]. The exact prevalence of allergic 
conjunctivitis in children with AR cannot be determined as the 
patients usually do not self report eye symptoms and do not 
attach much importance to it [1]. A study from China revealed 
that 430/485 (89%) children with AR had concomitant allergic 
conjunctivitis [33]. Allergen exposure of nasal or conjunctival 
mucosa may lead to inflammation at both the places probably 
due to anatomical contiguity. Intranasal corticosteroids have been 
shown to suppress nasal as well as ocular symptoms [34]. 
Patients with perennial AR are at a larger risk of developing 
sinusitis [35]. At our Institute, we found that 136/189 (72%) of 
subjects with AR had concomitant sinusitis [36]. The presence of 
sinusitis increased the morbidity in patients with AR especially in 
‘blockers’ and increased the incidence of postnasal drip (62/88 vs. 
15/43, p < 0.05) as well as sneezing (52/88 vs. 7/43, p < 0.05) [36]. 
Since sinusitis rarely occurs without rhinitis, the term ‘rhinosinusitis’ 
is frequently being used interchangeably with the term ‘rhinitis’ [1].   
Patients with AR also have a higher incidence of nasal polyposis 
which is considered to be a part of spectrum of chronic sinus 
pathology [37]. 
Allergy should be investigated in children with symptomatic 
adenoid hypertrophy [1]. Although the exact role of allergy in 
adenoid hypertrophy is unknown; the presence of sensitisation to 
inhalant allergens has been reported to alter the immunology of 
adenoid tissue which might have an aetiological role in adenoid 
hypertrophy [38]. Inflammation in AR can lead to mucosal swelling 
around eustachian tube. Tympanometery performed in 80 patients 
with AR and 50 healthy controls, comprising adults and children, 
demonstrated abnormalities in 15.5% of children below 11 years 
of age with AR [39]. In contrast, no abnormal curves were seen in 
healthy controls; thereby demonstrating that children with AR are 
at a greater risk of Eustachian dysfunction [39]. The presence of 
rhinitis or atopic eczema is significantly associated with a higher 
incidence of otitis media with effusion [38, 40].
treatment issues
The goals of management of AR, as described in the ARIA 
management pocket reference guide [41], include (i) no 
troublesome symptoms, (ii) performance of near normal daily 
activities without school absenteeism, (iii) no sleep impairment, 
and (iv) minimal or no side-effects of treatment. Allergen 
avoidance along with pharmacotherapy is the mainstay of 
treatment. Key allergens should be identified and avoided as far as 
possible. Oral/intranasal antihistamines along with INCS comprise 
the armamentarium against AR [1, 41]. However, self medication is 
very common, leading to both over as well as under-medication. 
While over-medication is associated with unnecessary costs and 
numerous side effects leading to increased morbidity, under-
medication leads to suboptimal control of symptoms which 
hampers quality of life [1, 2, 20, 21].
Currently, oral antihistamines are usually the first group of 
drugs to be prescribed in the pediatric population [1]. Since the 
first generation antihistamines cause sedation, drowsiness and apallergy.org
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anti-cholinergic side effects [42], they are best avoided lest they 
lead to impairment in performance and learning at school. The 
newer second generation antihistamines, which include cetirizine/
levocetirizine, loratadine/desloratadine and fexofenadine, have 
now emerged as the preferred drugs [1, 42].
Intranasal corticosteroids are the most effective form of 
therapy available till date [1]. The common INCS available are 
beclomethasone, triamcinolone, budesonide, fluticasone, 
mometasone and ciclesonide [1]. INCS have shown to improve 
nasal congestion and have demonstrated a reduction in sleep 
problems and daytime sleepiness among patients [43]. This is 
bound to improve quality of life during the day, reduce fatigue 
and eventually improve school performance in children [2, 
43]. However, dry nose, mucosal crusting and bleeding are not 
uncommon [44]. Other adverse effects of INCS include transient 
symptoms of nasal stinging, throat irritation, and even nasal septal 
perforation [45]. Due to undue fear of systemic effects and growth 
reduction, parents tend to avoid INCS for their wards.  Growth 
suppression in children due to INCS remains debatable though 
there is some evidence of its association with beclamethasone [46]. 
concLuSIon
AR, the commonest chronic pediatric disorder, is associated 
with a number of comorbidities and complications and is strongly 
linked with asthma. AR in children has a significant impact on the 
quality of life, negatively affects the family and impairs the process 
of learning. Irrational treatment in the form of under-treatment, 
over-treatment as well as use of inappropriate drugs, compound 
the problem. This is especially true for school going children in 
whom timely and appropriate treatment could possibly avoid the 
immense morbidity encountered with this disease. 
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